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Abstract

Development of methods to monitor cellular activity with magnetic resonance imaging
(MRI) provides a powerful tool for studying disease progression and monitoring therapy.
This thesis investigates components necessary for development of reporter gene
expression for MRI, to track Nkx2.5 transcription factor activity during tumour growth
and, in the future, to calibrate MR contrast against a well-known optical reporter gene,
like firefly luciferase. In human MCF-7 breast cancer cells, Nkx2.5 is induced by alltrans retinoic acid (tRA) and activates a minimal promoter of the rat sodium iodide
symporter (rNISmin) gene. Here, we used firefly luciferase reporter gene expression to
examine a human minimal sodium iodide symporter promoter (hNISmin) and showed no
response to Nkx2.5 or tRA treatment in MCF-7 cells, unlike rNISmin. The MRI reporter
gene studied is MagA, a putative iron transporter from magnetotactic bacteria that
increases iron accumulation in mammalian cells and influences the MRI signal to allow
cell tracking. HA and myc epitopes were cloned onto MagA and the iron accumulating
function of the resulting tagged-protein was studied. Elemental analysis of ironsupplemented MCF-7 cells transiently expressing either HA-MagA-myc or untagged
MagA demonstrated comparable iron content, significantly above the untransfected
control. While previous work has examined constitutive MagA expression, a reporter
gene expression vector with an interchangeable promoter, capable of expressing both
tagged MagA and luciferase, will provide a versatile construct for detecting tumourassociated transcription factor activity using MRI.

Keywords
Reporter gene expression, Magnetic resonance imaging, MagA, Firefly luciferase,
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Chapter 1

1

Introduction

1.1 Reporter Gene Expression
Reporter gene expression is a useful tool for monitoring transcriptional activation in cells
by the expression of a detectable protein. This tool can then be used to study the
pathways involved in gene expression, including identification of the temporal and spatial
expression of genes. Since transcription is the first step in gene expression, the factors
initiating this event are key to understanding the onset of cellular changes in both health
and disease. Transcription is typically regulated by the binding of transcription factors
(protein) to DNA response elements within the non-coding regions of the gene, that is,
the promoter. A reporter gene expression construct is a plasmid DNA vector wherein
select response elements are used to control the expression of a known gene (the reporter)
and its expression results in a detectable phenotype (Figure 1.1.1) [1]. Thus, the observed
phenotype reflects the molecular interactions occurring in the cell that led to expression
of the reporter gene. Such a tool, therefore, helps identify mechanisms involved in
cellular signaling pathways and has been used as a tool to analyze promoter activation,
monitor molecular activity, verify gene delivery and detect gene expression.
The objective of this thesis is to synthesize the DNA constructs necessary for the
development of reporter gene expression for magnetic resonance imaging (MRI), a novel
tool for detecting transcriptional activation in vivo. The work reported here studies
induction of the human sodium iodide symporter minimal promoter (hNISmin). If
hNISmin is activated in cancer cells by RA or Nkx2.5 (a transcription factor), as
determined for the rat sodium iodide symporter minimal promoter (rNISmin) [2], then
any reporter gene expression vector under the control of hNISmin (the promoter) will
permit detection of Nkx2.5 activity. In this thesis, the activity of hNISmin was measured
with the firefly luciferase reporter gene. However, to enable detection of Nkx2.5 activity
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in the future using MRI reporter gene expression, we modified the MagA gene [3] and
demonstrated its expression in and efficient iron labelling of breast cancer cells.

Figure 1.1.1. Reporter gene expression. The diagram depicts the key elements
of reporter gene expression. This type of construct contains promoter sequences
or response element(s) that control the expression of a gene, the reporter. A heavy
black line indicates 5ʹ′ phosphate and 3ʹ′ hydroxyl orientation of the DNA
construct. Transcription factor (protein) binding to promoter sequences (DNA)
activates transcription (bent arrow) of the reporter gene. Detection of the
corresponding protein or protein activity indicates that a molecular interaction
between the transcription factor and promoter/response element stimulated
expression of the reporter gene.
Many different types of vectors are commercially available that permit manipulation of
the promoter element and/or the reporter gene using molecular cloning tools such as
restriction enzyme digestion [4]. By introducing these reporter gene expression vectors
into mammalian cells, transcription factor activity and gene expression can be tracked in
both cell culture and transgenic organisms. In addition, the effect of experimental
treatments on transcriptional activation may be studied [4]. There are numerous reporter
genes used today, displaying various phenotypes that may be detected using different
2

modalities. For example, the reporter gene green fluorescent protein (GFP) emits light
detectable by fluorescence microscopy whereas β-galactosidase activity is identified by a
colorimetric assay [1]. The type of reporter gene used depends on what is being studied.
In this thesis, 2 reporter genes were studied: firefly luciferase and MagA, for the
development of a dual-modality reporter gene construct to detect transcriptional
activation by bioluminescence and MRI respectively.

1.1.1

Firefly Luciferase

Firefly (Photinus pyralis) luciferase is a well characterized and widely used reporter gene
because of its high sensitivity and broad detectable range. Luciferase activity proportional
to enzyme concentrations ranging up to 8 orders of magnitude (from 1 femtogram of the
enzyme) may be detected so that activation of weak promoters can still be identified [1,
5, 6]. The enzyme is 62 kDa and does not require post-translational modification [6, 7].
Its activity requires the substrates luciferin, ATP and O2. Luciferase catalyzes the
oxidation of luciferin in a multistep process. Luciferin first reacts with Mg2+ -ATP to
create an intermediate compound which is then oxidized to produce oxyluciferin (see
equation below). Oxyluciferin is an electronically excited compound that releases light
(560 nm) when it returns to ground state [6, 8]. The photon emitted is proportional to
enzyme concentration and can be quantified with a luminometer [6]. The reaction
happens very rapidly allowing for quick data collection, and many commercial assay kits
for luciferase analysis have been developed to stabilize the enzyme and prolong the light
produced [4, 5]. Furthermore, mammalian cells do not express luciferase so detectable
activity is above cellular background [4].
Luciferin + ATP + O2 à oxyluciferin + AMP + PPi + CO2 + light
[4, 6]
Transfection of cells with luciferase often requires a co-transfection control since the
amount of vector DNA that cells incorporate when transiently transfected can vary
between different culture plates despite controlled conditions [4]. For instance, cell
number and viability may differ between plates and this may result in a difference in
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transfection efficiency. A co-transfection control vector with a reporter gene unaffected
by the experimental treatment is used to normalize data relative to the efficiency of
transfection and cell lysis. For instance, the use of Renilla (Renilla reniformis, known as
sea pansy) luciferase as a co-transfection control is often used when transfecting with
firefly luciferase [6]. Since Renilla luciferase has a different substrate than firefly
luciferase, and emits light at a wavelength of 482 nm, the two luciferase reactions can be
conveniently carried out in the same vessel and detected sequentially with the same plate
reader [6]. Commercial luciferase assay kits have thus been developed that permit the
detection of both firefly and Renilla luciferase activities within the same sample [5].
Substrate addition and light measurement for each enzyme is accomplished sequentially
using a quenching agent in between each reaction to silence the initial signal. This makes
for fast and reliable detection of each luciferase activity.
In summary, firefly luciferase as a reporter gene allows for sensitive detection of
transcriptional activation. This makes it possible to detect minute changes in promoter
activation from small quantities of transiently expressed vector [4]. Adequate firefly
luciferase activity may be detected from approximately 1 femtogram of the enzyme [5].
In comparison, the reporter gene chloramphenicol acetyltransferase is detectable down to
1 picogram [4]. The luciferase reaction is fast and can easily be measured in cell lysates
using a luminometer. Firefly luciferase is a widely used reporter gene [1, 4].
Disadvantages of its use include requiring the substrate, and ATP and O2. In addition,
transfection efficiency must be controlled for. However, recent developments in
luciferase assays such as reagents that stabilize the enzyme and accommodate for a cotransfection control have allowed for reliable detection of its activity [5].

1.1.2

Reporter Gene Expression in MRI

Developing reporter gene expression for MRI enables long-term monitoring and
detection of specific transcriptional activity using a non-invasive imaging modality.
Many of the current non-MRI reporter genes are limited to cell culture applications or
require invasive methods of detection [1, 9]. Some reporter genes such as GFP and
4

luciferase have been expressed in small animal models but light scatter and absorption
make it difficult to image deep tissues using optical techniques [10]. A reporter gene for
MRI would permit not only cell localization with superb anatomical context, but also
temporal and spatial imaging of specific protein activity using reporter gene expression
vectors.
MRI is an imaging modality that uses a sample’s magnetic properties to create an image.
Because of this it is non-invasive and has no ionizing radiation [11]. Contrast agents are
often used in MRI to better distinguish between different samples or tissues. For instance,
Gadolinium is often used in the clinic to enhance blood vessels or image lesions [11].
Contrast agents work by altering the MRI signal. Recently much work has been done in
developing methods to track cells with MRI using contrast agents [10]. Development of
these tools will permit non-invasive, temporal imaging of cells and may be used to
investigate the progression of disease in preclinical models or to monitor stem cell
therapy.
Much of the work with cell tracking in MRI has been with the use of iron oxide particles.
[10]. Iron has a strong effect on the MRI signal by causing it to decay quickly. The rate at
which a signal decays is known as the transverse relaxation rate. Iron particles increase
transverse relaxation rate and result in regions of hypointensity in MRI [12].
Superparamagnetic iron oxide (SPIO) particles are clinically approved and have been
used in clinical studies to label dendritic cells, and stem cells [12–14]. SPIO-labeled
neural stem cells injected into a patient with brain injury showed hypointensity that
changed overtime [13]. This dynamic hypointensity was absent in the control group and
was attributed to migration of the labeled stem cells. However, this contrast disappeared
at 7 weeks and was speculated to be due to contrast dilution from cell proliferation [13].
Micron-sized iron oxide particle (MPIO) cell labeling enabled single cell localization of
migrating, transplanted hepatocytes in mice one month following cell injection [15].
Also in mice, MPIO were used to detect the formation of breast cancer brain metastases
from the single cell stage [16].
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Cells labeled with iron oxide particles are able to impart contrast immediately so that
transplanted cells may be detected right after delivery. However, exogenous contrast
agents like iron oxides are diluted as the cells divide and so the MRI contrast is
eventually lost [10, 12]. For example, MPIO-labeled breast cancer cells were detected in
the brain 3 days following injection in the heart but by day 28 the contrast observed from
the tumours formed was no longer due to the MPIO [16]. Contrast from these agents also
does not reflect cell viability [17]. Cells with the contrast agent will continue to have that
MR signal whether they are viable or not.
Gene-based contrast agents permit long-term cell tracking and, more importantly, have
the potential for reporter gene expression [18]. Since the agents are gene-based, gene
replication prior to cell division prevents dilution of the agent. Cells may be genetically
engineered to express genes whose activities alter relaxation rates. Some of the work in
this field uses ferritin, an iron storage protein expressed in most organisms including
mammals. The cytosolic protein is capable of storing up to 4000 iron particles in a ferric
oxyhydroxide core [18]. Overexpression of modified ferritin, lacking iron response
elements to enable continuous overexpression, has been used to image transplanted stem
cells and track tumour formation [19, 20]. Contrast from the overexpression of the heavychain ferritin subunit was still observed in C6 rat glioma tumours 28 days post cell
transplantation [19]. A recent study by Naumova et al. directly compared iron oxide
labeled cells with ferritin-overexpressing cells [17]. In this work, mouse skeletal
myoblasts, either labeled with SPIO or engineered to overexpress ferritin, were injected
into the infarcted region of the heart of mice and imaged at 3 Tesla. The signal change
was greater in SPIO-labeled cells than in ferritin overexpressing cells but showed the
same signal with dead cells. Ferritin overexpressing cells, on the other hand, identified
live cells [17].
Ferritin has also been used as a reporter gene to image transgenic mice [21]. Mice were
engineered to express the ferritin heavy chain in vascular endothelial cells and liver
hepatocytes using a tetracycline response element, activated only by induction of tissue
specific promoters: the vascular endothelial cadherin promoter and the liver activating
6

protein promoter. Specific changes in transverse relaxation rate were observed in the
mice in utero and as adults [21]. Contrast changes in the transgenic mice verified both the
spatial and developmental expression of the organ specific transcription factors.
In summary, developing reporter gene contrast agents for MRI will improve longitudinal,
non-invasive detection of cellular activity. Furthermore, designing reporter gene
expression for MRI, where expression of the contrast signal is activated by specific
transcription factors, enables detection of molecular interactions in the cells. This will be
a useful tool for studying molecular mechanisms involved in the development and
progression of disease or for monitoring the efficacy of stem cell transplantation. Ferritin,
as an MRI reporter gene, shows promising results by creating contrast due to iron.
However, there are other iron handling proteins that may impart greater changes in MRI
contrast [22].

1.1.3

MagA as an MRI Reporter Gene

MagA is a putative iron transport protein with demonstrated potential as a gene-based
contrast agent for MRI. MagA is expressed in some magnetotactic bacteria, including
Magnetospirillum magneticum strain AMB-1 [23] and Magnetospirillum
magnetotacticum strain MS-1 [24]. These strains belong to a class of bacteria that
synthesize intracellular magnetic particles in the form of magnetite (Fe3O4) [18, 25].
These magnetic particles, called magnetosomes, are enveloped by a lipid bilayer and are
believed to be used in magnetotaxis [22]. Analysis of MagA reveals homology to integral
membrane antiport proteins found in other bacteria, such as the potassium membrane
transport protein of Escherichia coli (E.coli) and the sodium anti-porter expressed in
Enterococcus hirae [23, 26]. Using a luciferase reporter construct, expression of MagAluciferase fusion protein in AMB-1 was localized to the cytoplasm, bacterial cell
membrane and magnetosome membrane [26]. In E.coli overexpressing MagA, iron
accumulation was also observed in isolated vesicles [23]. Despite this evidence, the role
of MagA in magnetosome formation has been recently questioned. The MagA gene is not
present in all magnetotactic bacteria and is not found within the bacterial magnetosome
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genomic island, a region of conserved nucleotide sequences (operons) encoding most of
the genes necessary for magnetosome formation [27]. AMB-1 with a MagA deletion still
formed magnetosomes similar to those of the wild-type bacterium [27]. Together these
results suggest that MagA is not essential for magnetosome formation. However, the
absence of MagA from the magnetosome island does not exclude it completely from a
role in the synthesis of magnetosomes. Of the 28 genes attributed to magnetosome
formation, 10 are not within the magnetosome island and very few appear to be essential
to magnetosome synthesis [22, 28]. Moreover, MagA overexpression in several
mammalian cell lines results in increased iron accumulation [3, 24, 29, 30].
Overexpression of MagA in mammalian cells consistently results in changes in the MRI
signal without introducing cytotoxicity. MagA expressed in the human cell line 293FT
resulted in the formation of magnetic, iron-oxide particles and increased transverse
relaxation rate [24]. Analysis of the iron particles using X-ray power diffraction
identified these as magnetite [24]. In vivo, mouse xenografts formed from transplanted
MagA-expressing MDA-MB-435 cells displayed contrast enhancement above the
parental control over several weeks of tumour growth [31]. In vitro studies using gelatin
phantoms showed increases in transverse relaxation rates in iron-supplemented MagA
expressing cells, comparable to that of the modified ferritin subunits. Mass spectrometric
analysis of these same cells showed increased iron accumulation in response to an
extracellular iron supplement [3]. More recently, inducible MagA expression in a mouse
embryonic stem cell line showed no adverse effects on cell pluripotency in vivo while
providing significant changes in transverse relaxation rate [29]. MagA has yet to be used
as a reporter gene to track the activity of specific intracellular transcription factors.
Use of magnetotactic bacterial genes for MRI reporter gene expression is attractive for
many reasons. These bacteria synthesize iron biominerals consisting of magnetite, which
has a magnetization that is 100-fold greater than ferritin [32]. We are interested in using
MagA to demonstrate the potential use(s) of magnetosome-like particles for the detection
of reporter gene expression by MRI. This permits non-invasive imaging of cellular
activity making it possible to image large animal models or monitor stem cell
8

transplantation. In addition, gene-based cell contrast for MRI circumvents the problem of
contrast dilution allowing for long-term imaging. Such a tool is useful for localizing
transplanted stem cells or imaging tumour growth and metastasis. MagA has potential in
being a reporter gene for MRI because it is not cytotoxic, has the ability to enhance
cellular iron accumulation and change transverse relaxation rates in an iron-dependent
fashion. Importantly, MRI reporter gene expression will enable the study of cellular
mechanisms involved in pathology by the monitoring of temporal and spatial
transcription factor activity (i.e. promoter activation).

1.2 Nkx2.5
As a homeobox protein, Nkx2.5 is a transcription factor that has homeodomain regions
involved in early development and morphogenesis by regulating gene expression, and is
part of the NK2 class of transcription factors [33]. Conserved domains within this class
are the TN, the homeodomain, and the NK2 specific domain (NK2-SD) [34, 35]. NK2SD regulates the activation domain of the transcription factor, whereas the homeodomain
is the DNA-binding region [34, 35]. The NK2-SD has a core amino acid sequence of
VAVPVLV and is characteristic of the NK2 class of transcription factors [34]. The DNA
binding sequence of Nkx2.5 is TNAAGTG, and also has a moderate to weak binding
affinity for C(A/T)TTAATTN [33].
Nkx2.5 is a 60-amino acid protein expressed in mouse embryos in the developing heart,
thyroid primordium, spleen, stomach and tongue [36]. This embryonic expression of
Nkx2.5 is estimated to begin as early as 7.5 days postcoitum and contributes to
myocardial differentiation. Deletion of Nkx2.5 in knock-out mice results in embryonic
lethality at 9-10 days postcoitum due to abnormal heart development, wherein the heart
failed to properly loop and form chambers [37]. Expression of Nkx2.5 in the developing
mouse heart is activated by GATA4, another transcription factor involved in early
cardiogenesis [38]. In adult mice, Nkx2.5 is predominantly expressed in cardiomyocytes
[36]. However, in humans Nkx2.5 is associated with some diseases. Mutations in Nkx2.5
are implicated in congentital heart disease and thyroid dysgenesis [39, 40]. In addition,
9

Nkx2.5 overexpression is found in myotonic dystrophy, a type of muscular dystrophy
[41].
Nkx2.5 is a transcription factor that may also play a role in cancer. The Nkx2.5 gene in
colon cancer has significantly greater methylation compared to the gene expressed in
normal colon [42]. In the study by Dentice et al., Nkx2.5 induced thyroid specific
promoters in luciferase reporter plasmids, and in particular, the sodium iodide symporter
(NIS) in HeLa cells, a human cervical cancer cell line [2]. Overexpression of Nkx2.5
activated the full promoter of rat NIS about 25-fold. Truncation of the rat NIS promoter
indicated that a 470 bp sequence, proximal to the start of transcription, was required for
maximal activation of luciferase reporter gene expression by Nkx2.5 overexpression. An
electrophoretic mobility shift assay (EMSA) indicated that Nkx2.5 binds to 2 regions
within this rat minimal promoter. Activation of this minimal promoter in the presence of
Nkx2.5 overexpression produced a ~40-fold increase in luciferase reporter gene activity.
Furthermore, all-trans retinoic acid (tRA) was found to induce Nkx2.5 expression in the
Michigan Cancer Foundation-7 (MCF-7) cell line. Quantitative, reverse transcriptionPCR (RT-PCR) showed that treatment of these cells with 1µM tRA for 6 h increased
endogenous Nkx2.5 expression ~8-fold and was followed by a ~16-fold increase in NIS
expression 12 h later [2]. The authors concluded that tRA-induced expression of Nkx2.5
in MCF-7 cells activates the minimal rat NIS promoter and results in functional human
NIS expression. This response has yet to be demonstrated with the minimal human NIS
promoter.
In the same study, Nkx2.5 expression was detected in 2 human breast carcinoma samples
that also displayed NIS activity [2]. Since the expression of functional NIS in thyroid
cancer permits effective radioiodide treatment and detection of metastases [43],
investigation of the mechanism of human NIS induction in breast cancer with respect to
the role of Nkx2.5 may help to develop therapy and imaging tools for the disease.

1.2.1

Sodium Iodide Symporter

The NIS is responsible for the uptake of iodide from blood into the thyroid gland. Iodide
is used by the body to create thyroid hormones which are necessary for metabolism [44].
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NIS is also expressed in other tissues such as the gastric mucosa, salivary glands and
lactating mammary gland [44]. Its function in these extrathyroidal tissues is largely
unknown, but in the lactating mammary gland, it is used to accumulate iodide in the milk
which the newborn requires for proper development [45, 46]. NIS is expressed in
differentiated thyroid cancers [47] where its expression aids in the effective imaging and
treatment of the tumour with the use of radioiodide [43]. NIS expression has been
detected in breast cancer, presenting the potential of using radioiodide for the treatment
of this disease [46]. Therefore, understanding how NIS expression is regulated will aid in
the development of imaging and therapeutic tools for cancer.
Function
NIS is a glycoprotein with 13 transmembrane domains and is expressed in the plasma
membrane on the basolateral side of the thyroid follicular cells [45]. Iodide is transported
into the lumen of thyroid follicles where it is oxidized and conjugated with thyroglobulin
in a process called organification. The tissue accumulates approximately 60 µg of iodide
per day [48].
NIS expression in the thyroid is induced by thyroid stimulating hormone (TSH) [48]. In
addition to activating NIS expression, TSH also targets the protein to the plasma
membrane. In culture, thyroid cells show increased NIS expression in both the plasma
membrane and the membranes of intracellular compartments. Upon withdrawal of TSH
the rate of decrease of NIS from the plasma membrane was greater than that from
cytoplasmic NIS suggesting that the transporter is redistributed, away from the plasma
membrane, in the absence of TSH [49].
Iodide uptake also occurs in the lactating mammary gland, which accumulates iodide in
the milk up to concentrations between 20-700 µg/L[50]. The newborn requires iodide to
produce thyroid hormones necessary for proper development of the nervous system and
skeletal muscle [46]. Normally, estrogen, oxytocin and prolactin induce the expression of
NIS during lactation [46].
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Relevance in Cancer
The expression of NIS in most thyroid cancers permits effective treatment of the disease
using iodide uptake strategies and significantly improves prognosis. Radioiodide is used
to detect and destroy thyroid cancer tissue and metastases making NIS-expressing thyroid
cancer one of the most manageable, with a survival rate of 85-92% [48]. Though NIS in
thyroid cancer is cytosolic and accumulates little iodide, treating the patient with TSH
results in increased iodide uptake in the tumour [45, 48]. Patients with differentiated
thyroid cancer treated with radioiodide have a decreased mortality rate of 3% compared
to patients not treated with radioiodide (12%) [45]. The success in the management of
thyroid cancer has led to exploring the potential of using NIS and radioiodide for
treatment of other cancers. For instance, NIS was used in a gene therapy study on
prostate cancer resulting in a decrease in tumour volume [51]. Some breast cancers
overexpress NIS. Understanding NIS induction and expression in cancer will help in
developing radioiodide as an effective treatment, as it has been in the thyroid.
Breast Cancer
NIS is expressed in some breast cancers and has great potential in detecting and treating
such tumours. NIS is expressed in 80% of breast cancers and iodide uptake has been
observed in breast cancer models [46, 48]. Protein analyses show the transporter in the
intracellular space [46, 48]. This is similar to its expression in thyroid cancer where
cytosolic NIS does not result in high iodide uptake [48]. Out of 25 primary breast tumor
samples that expressed NIS, only 4 took up 99mTcO4- [52]. In differentiated thyroid
cancer, increasing TSH in patients results in radioiode uptake by localizing NIS to the
plasma membrane [45].
There are differences in NIS regulation in normal extrathyroidal tissues, including the
breast, as well as in regulation of NIS in breast and thyroid cancer. In the lactating
mammary gland, NIS expression is induced by prolactin, oxytocin and estrogen [46]
while most of the work on NIS expression in breast cancer has used the MCF-7 cell line,
an estrogen receptor expressing breast cancer cell line [48]. MCF-7 expression of NIS
results in a low level of iodide uptake [53]. Several studies have looked at induction of
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the symporter in this cell line using agents such as retinoic acid (RA), human chorionic
gonadotropin (hCG), insulin and prostaglandin [48]. Treatment with prolactin resulted in
an increase of NIS protein and 10-fold increase in iodide uptake; however, this effect
only lasted for 12 h [53]. hCG and prostaglandin also increased iodide uptake in MCF-7
by 4 and 2.5 –fold respectively [54]. Insulin and insulin-like growth factor increased NIS
protein and iodide uptake by 11-fold, but, like prolactin, this effect was transient [53].
While all these hormones resulted in an increase in iodide uptake, the greatest of all was
the effect of RA. RA treatment of MCF-7 cells resulted in a ~9-fold increase in iodide
uptake which lasted up to 72 h [48, 55].
Transgenic mice with mammary adenocarcinoma showed 99mTcO4- uptake but at levels
lower than that of lactating mammary gland [46]. NIS expression in the thyroid is
followed by iodide organification which retains the iodide in the follicular lumen of the
tissue [48]. There is a concern that induction of NIS expression in non-thyroidal tumours
may not be effective because the cells may not be able to retain radioiodide. In one gene
therapy study, NIS was delivered to prostate tumours using an adenovirus; tumours were
then treated with radioiodide. This resulted in iodide uptake and a subsequent decrease in
tumor volume by 84% [51]. Although these cells were unable to organify iodide, the
results suggested that organification of radioiodide is not necessary for treatment
effectiveness. This promising finding has supported the use of radioiodide for treatment
of cancer.
Thus, induction of NIS expression in breast cancer might be useful in diagnosing and
treating the disease. Just as radioiodide in thyroid cancer is able to detect and destroy
occult micro-metastases in addition to un-resected tissue [43, 47], in breast cancer NIS
expression may also be used as a diagnostic tool. In addition, the prevalence of NIS in
breast cancer (80%) is greater than that of Her2/neu (33%), the biomarker widely tested
for [45]. This and the evidence for effective radioiodide therapy in other cancers further
emphasizes the importance of understanding the induction of expression and activity of
NIS in breast cancer.
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Induction of the Sodium Iodide Symporter in Breast Cancer
RA stimulates increased iodide uptake in thyroid and breast cancer [48]. RA, a metabolite
of vitamin A, is a ligand for both the nuclear retinoid X receptor (RXR) and RA receptors
(RAR) and affects development and cell differentiation [48]. As thyroid cancer
progresses, there is often a loss of differentiation, a morphological change in the tumor
resulting in a more aggressive phenotype and loss of iodide uptake [56]. In one clinical
study, 50% of patients with advanced thyroid cancer, treated with RA for 5 weeks
showed increased iodide uptake [56]. However, in another study of 12 patients treated
with RA for 2 months, only 2 showed significant increases in iodide uptake while 3 had a
faint response [57]. While RA affects thyroid cancer redifferentiation in vitro and in vivo,
the variable and sometimes mild clinical response indicates that other factors are involved
in the induction of NIS by RA [56].
Treatment of MCF-7 cells with tRA has shown promising results. In vitro, RA treatment
of MCF-7 cells resulted in a ~9-fold increase in iodide uptake that lasted 36-72 h [55]. In
vivo, MCF-7 mouse xenografts showed a 15-fold increase in iodide uptake [58]. A recent
study by Alotaibi et al. using luciferase reporter gene expression suggests that RA
stimulates human NIS expression by activating an RA response element (RARE) found
in the first intron (+1222 relative to the start codon) of the NIS gene [59]. Deletion of this
RARE eliminated the induction effect by RA in MCF-7 cells. In the same study, a
promoter region, -1138 to -42 relative to the start codon of the NIS gene, also activated
gene expression following RA treatment [59]. A RARE was also identified upstream in
this same (proximal) promoter region [60]. In follicular thyroid cancer cells, tRA induces
NIS expression by activating this proximal RARE. However in MCF-7 cells, subsequent
mutations in that promoter region showed that the entire region, not only the RARE, was
necessary for tRA induction suggesting a synergistic response between the regions in that
proximal promoter [59].
Minimal Sodium Iodide Symporter Promoter and Nkx2.5
In an effort to identify the mechanism of RA induction of NIS in MCF-7 cells, Dentice et
al. used rat NIS and showed that RA increases the expression of the homeodomain
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protein Nkx2.5 [2]. This transcription factor then binds to two regions within a minimal
promoter (-470 to +1 relative to the start codon) of the rat NIS gene thus activating its
expression.
Nkx2.5 mRNA was detected in 2 human breast carcinoma tissue samples and in the
lactating mammary gland but not in adult thyroid or the non-lactating mammary gland
[2]. Nkx2.5 may play a role in the development of breast cancer or may potentially be
regulated to aid in therapy. Most thyroid cancers express NIS which enables imaging and
treating the disease with radioiodide [43, 47]. Stimulation of functional NIS in thyroid
cancer is achieved by increasing TSH, resulting in increased radioiodide uptake for
ablation of the tumour. However, NIS regulation in breast cancer differs from that of
thyroid and the mechanism is not well understood [48]. Understanding how NIS
expression is stimulated in breast cancer will help in developing an effective treatment
and imaging method for the disease. To this end, it is important to create a tool that
allows for the non-invasive and long-term detection of potential factors, such as Nkx2.5,
which may be active in the development and progression of the disease.

1.3 Thesis Objectives
Reporter gene expression is able to detect transcriptional activation in cells. This
technology provides insight into signaling pathways involved in gene expression and
disease. The novel application of MagA reporter gene expression for MRI will enable
temporal and spatial detection of protein activity and may be useful for investigating
factors involved in the development and progression of disease, and monitoring cell
therapy. Development of such an MRI reporter gene expression construct will allow for
the non-invasive, long-term detection of molecular interactions within the cell, such as
the oncogenic factors that stimulate NIS expression.
The work described in this thesis contributes to development of an MRI reporter gene
expression construct by investigating two of the components: the promoter, hNISmin,
and the reporter, MagA. More specifically, the goal of this project is two-fold: firstly, to
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create a luciferase reporter gene expression construct using the hNISmin and investigate
its induction by Nkx2.5 and RA in the human cancer cell lines MDA-MB-435 and MCF7, as demonstrated with the rNISmin; and secondly, to create a doubly tagged MagA gene
construct using HA- and myc- epitopes cloned onto the 5ʹ′ and 3ʹ′ terminals of MagA,
respectively. These epitopes will permit verification of MagA protein expression and
potential processing. Synthesis of these two DNA constructs are important steps in the
development of reporter gene expression for MRI to track Nkx2.5, in the characterization
of hNISmin in human cancer cell models, and in the calibration of MagA-derived MR
signal fluctuations against a sensitive and well-characterized optical reporter. Although
this introduction has considered implications of MRI reporter gene development and of
understanding the mechanism of NIS for cancer therapy, it is important to emphasize that
the goal of this thesis is directed toward the development of a reporter gene for MRI. The
reporter gene would be used for studying cancer development in an animal model.
Chapter 2 of the thesis describes synthesis of, and experimentation with, an hNISminluciferase reporter vector. Induction of hNISmin by RA and Nkx2.5 was tested in two
cancer cell lines, MCF-7 and MDA-MB-435, by measuring firefly luciferase activity.
While the rNISmin responded to RA activation and an increase in Nkx2.5 expression [2],
this has yet to be demonstrated for hNISmin. Creating a tool to detect the temporal and
spatial activity of Nkx2.5 in breast cancer models in vivo will help in understanding how
NIS expression is induced in breast cancer and the role of Nkx2.5.
Chapter 3 describes the cloning strategy for the synthesis of the HA-MagA-myc gene.
The HA- and -myc epitopes will permit detection of MagA protein expression using
commercial antibodies. MagA is inserted through several vectors to create the final
construct and iron uptake is analyzed in transfected MCF-7 cells by mass spectrometry.
The epitopes will verify the expression of MagA as it acts as an MRI reporter gene.
Insertion of HA-MagA-myc into the hNISmin-driven luciferase reporter gene expression
construct discussed in chapter 2 will make it possible to measure both MagA-derived
contrast and luciferase activity in the same cells and correlate bioluminescence with the
MR signal.
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Finally, chapter 4 summarizes the results of induction of hNISmin by RA and Nkx2.5,
and creation of a functional HA-MagA-myc. The potential of using hNISmin as a
promoter for MRI reporter gene expression with HA-MagA-myc is discussed. NIS
expression in breast cancer presents a potential use for radioiodide treatment of the
disease but much work needs to be done in understanding NIS induction.
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Chapter 2

2

Induction of the human minimal sodium iodide
symporter promoter by RA and Nkx2.51

2.1 Introduction
Reporter gene expression enables the detection of transcription by the activation of a
promoter or response elements and the expression of a detectable protein. This is useful
in identifying molecular interactions in the cells and studying gene regulation. More
importantly, reporter gene expression helps in understanding the function of transcription
factors and other proteins in disease and therapy. NIS is a protein that has a potential role
in the treatment of breast cancer. It is primarily expressed in the thyroid and is
responsible for iodide uptake into the gland [1]. It is also expressed in thyroid cancer and
allows for the treatment of the disease and detection of metastases by administration of
radioiodide [2]. Radioiodide treatment of thyroid cancer in conjunction with
thyroidectomy decreases mortality (5%) compared to those not treated with radioiodide
(12%) [3]. As well, rate of metastases decreases [2]. NIS is also expressed in lactating
mammary gland [4]. Uptake in the tissue supplies the newborn with the iodide necessary
for proper development. NIS is expressed in 80% of breast cancers and breast cancer
metastases making radioiodide a potential imaging tool and treatment method for the
disease [5, 6].
Regulation of NIS expression in extra-thyroidal tissue differs from that of the thyroid and
is not as easily understood [7]. In breast cancer, some studies have shown that the
addition of RA increases NIS expression [7]. Although the mechanism of NIS regulation
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in breast cancer by RA is not fully understood, a study by Dentice et al. showed that RA
induces the expression of Nkx2.5, a transcription factor, which in turn activates a
minimal promoter of rat NIS by binding onto 2 sites named N2 and W. That study was
conducted in the breast cancer cell line MCF-7 [8]. This has yet to be demonstrated using
human NIS. In another recent study by Alotaibi et al., RA induced human NIS expression
by activating an intronic site of the gene [9]. Understanding how the expression of
functional NIS is regulated in breast cancer is an important step in the development of
radioiodide as a treatment method.
The aim of the present work is to construct a firefly luciferase reporter gene expression
construct using the hNISmin promoter and to verify its induction by Nkx2.5 in the MCF7 and MDA-MB-435 cell lines. We hypothesized that hNISmin will be induced by
Nkx2.5 and RA, similar to the response of rNISmin, and that treatment of transfected
cells with RA or Nkx2.5 overexpression will result in bioluminescence from a luciferase
reporter.

2.2 Methods
Study Design
To determine if retinoic acid (RA) and Nkx2.5 induce the hNISmin promoter in breast
cancer cells as observed in rNISmin, a firefly luciferase reporter gene expression
construct was created using hNISmin cloned from MDA-MB-435, a human cancer cell
line. Two cell lines were used for reporter gene expression: MCF-7, a human breast
cancer cell line and MDA-MB-435, a human melanoma cell line. These cell lines were
transiently transfected with either a constitutively-expressing luciferase reporter gene
expression vector (pSF-CMV), the hNISmin-driven vector (pSF-NISmin) or a
promoterless vector (pSF). Constitutive expression of firefly luciferase (Fluc) driven by
the cytomegalovirus promoter (CMV) acts as a positive control; whereas, removal of
CMV (in the promoterless pSF construct) provides a negative background control. In
addition, cell samples were co-transfected with a constitutively-expressing Renilla
luciferase (pRL-SV40), to control for transfection and lysis efficiency (Figure 2.2.1).
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Samples were treated with 1 µM all-trans-RA (tRA; 1 mM stock dissolved in
ethanol)/medium and cultured for an additional 12 h or left untreated prior to cell harvest
(Figure 2.2.2). To modulate the reporter gene expression signal, co-transfections were
performed using pCS2-Flag/Nkx2.5, to constitutively express Nkx2.5 (Figures 2.2.1 and
2.2.2). The samples were collected 36 h post-transfection and luciferase activity was
measured. Firefly luciferase activity was normalized to the internal control (Renilla
luciferase) and these values are reported as relative light units (RLU). The results were
analyzed to determine if treatment with RA or Nkx2.5 over-expression affects hNISmin
activation in the two cancer cell lines. A total of 4 wells were used per treatment, per cell
line (Figure 2.2.2).

Figure 2.2.1. Schematic of expression vectors used. pSF-CMV is the positive control
vector, wherein constitutive expression of firefly luciferase is driven by the CMV
promoter. pSF is the promoterless, negative control vector, and pSF-NISmin is designed
for expression of firefly luciferase driven by hNISmin. The pSF vectors have a multiple
cloning site (MCS) preceding an internal ribosomal entry site (IRES) from
Encephalomyocarditis virus (EMVC) to permit expression of two genes from a single
promoter (e.g., MagA and FLuc, in the future). pRL-SV40 was used as an internal
control, producing high constitutive expression of Renilla luciferase driven by the SV40
promoter. pCS2-Flag/Nkx2.5 constitutively expresses Flag-tagged Nkx2.5 driven by the
CMV promoter.
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Firgure 2.2.2 Schematic of the study design. MCF-7 and MDA-MB-435 cells were
transfected with either pSF-CMV, pSF-NISmin or pSF. These transfections were either
untreated or treated with 1µM RA (+RA) for 12 h. A third treatment group for the pSFNISmin and pSF- transfected group was the overexpression of Nkx2.5 (+Nkx2.5) by a
co-transfection with pCS2-Flag/Nkx2.5. There were four samples for every treatment
group per transfection for each cell line.
Reporter Gene Development
DNA amplification of hNISmin using the Polymerase Chain reaction
A nested polymerase chain reaction (PCR) was used to amplify hNISmin from
genomic DNA (gDNA) of MDA-MB-435 using Invitrogen Platinum® Taq DNA
polymerase High Fidelity, dNTP Set (Life Technologies) and a Bio-Rad thermocycler,
MyCycler™ model. The nested PCR allows for specific amplification of the target
gene by performing the reaction twice, using two primer oligonucleotide sets and
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using the first reaction as template for the second. Custom primers were synthesized
by Sigma-Aldrich and resuspended in sterile water to a concentration of 10 μM.
The first round of PCR was performed according to published procedures [10] using
1μg gDNA and the following reaction conditions: 1.5 μl 50 mM MgCl2 and 3 μl
dimethyl sulfoxide (DMSO). Primers are listed in Table 2.2.1. The amplification
described here employed NIS forward (NISf) and reverse (NISr). Thirty cycles of PCR
were performed according to the following scheme: 94 oC for 30 s, 55 oC for 45 s, 72
o

C for 30 s.

In the second round of PCR, 1μl from the first reaction was used as template, with 1 μl
50 mM MgCl2 and 1 μl DMSO. The new forward and reverse primers NIS2f and
NIS2r, respectively, are indicated in Table 2.2.1. The thermocycler program employed
30 cycles and the following scheme: 94 oC for 30 s, 55 oC for 30 s, 72 oC for 30 s.
DNA amplification was verified by 1% agarose gel electrophoresis. The final PCR
reaction gave a 553 bp band (hNISmin, Figure 2.3.1) and was directly cloned into
pCR2.1-TOPO using the TOPO® TA® Cloning Kit (Invitrogen) and 1μl of the nested
PCR product (hNISmin fragment). The TOPO reaction and TOP10 transformation
were carried out as recommended by the manufacturer. The transformation reaction
(50 µl) was plated on LB agar containing 200 µg/ml ampicillin (Life Technologies)
and incubated overnight at 37oC. Colonies were selected the following day and
screened for the DNA of interest by restriction enzyme digestion with EcoRI.
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Table 2.2.1. Custom oligonucleotides used in PCR, DNA sequencing and RT-PCR.
Oligonucleotide	
  

Orientation	
  

Sequence	
  (5’	
  to	
  3’)	
  

NISf	
  

Sense	
  strand	
  

GGTGCATGGGGATGGAGGGGCATTTGGGAGC	
  

NISr	
  

Anti-‐sense	
  strand	
  

GGACACCAGGAGCATGAGGGCAAAGACC	
  

NIS2f	
  

Sense	
  strand	
  

TGTCCTGGCCTGTCTGTCCC	
  

NIS2r	
  

Anti-‐sense	
  strand	
  

CCCCGTAGTCCCAGGCTCCG	
  

OGP-‐F1	
  

Sense	
  strand	
  

TCGTTGCGTTACACACAC	
  

Flag-‐Nkx2.5	
  

Sense	
  strand	
  

GATTACAAGGACGACGACGATAA	
  

Nkx2.5r	
  

Anti-‐sense	
  strand	
  

CTGCACCGCGTTCAAGTCCCCGAC	
  

	
  
Reporter gene expression vector
The reporter gene expression plasmid, pSF-CMV, containing a puromycin (Ub-Puro)
selection marker was purchased from Oxford Genetics (Figure 2.2.3). The constitutive
CMV promoter was removed by restriction enzyme digestion with BglII and the vector
backbone was religated to create a promoterless vector control, pSF (Figure 2.2.3).
To create the hNISmin reporter construct (pSF-NISmin), pSF was digested with BglII
and NotI and ligated with hNISmin, retrieved from pCR2.1™-TOPO® by digestion with
BamHI and NotI (Figure 2.2.3).
As an internal control for the bioluminescence assay, pRL-SV40 was used as is. Nkx2.5
over-expression was examined using the pCS2-Flag/Nkx2.5 vector provided by Dr. Ilona
Skerjanc, University of Ottawa.

30

Figure	
  2.2.3.	
  Cloning	
  Strategy	
  for	
  the	
  synthesis	
  of	
  an	
  hNISmin-‐driven	
  reporter	
  gene	
  
expression	
  construct.	
  CMV from pSF-CMV was removed by restriction enzyme
digestion using BglII. A PCR amplified fragment of the proximal human NIS promoter,
hNISmin, was cloned into pCR®2.1-TOPO® and inserted into the promoterless pSF
vector to create the reporter gene expression construct pSF-NISmin.	
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DNA sequencing
Plasmid vectors were validated by DNA sequencing, performed by the London Regional
Genomics Centre (Western University). Oligonucleotide primers were either provided by
the sequencing facility or by custom synthesis (Sigma-Aldrich, Table 2.2.1, OGP-F1).
Sequences were analyzed using SnapGene® software by GSL Biotech. Clustal Omega
1.2.1 Multiple Sequence Alignment tool was used to align nucleotide sequences [11, 12].
The algorithm aligns sequences to give the highest percent pairwise identity score.
Cell Culture
MCF-7 is a human, mammary gland adenocarcinoma cell line, expressing NIS and
exhibiting a low level of iodide uptake [13]. Dentice et al. used this cell line to show
induction of rNISmin by RA and Nkx2.5 [8]. MCF-7 cells were provided by Dr. Moshmi
Bhattacharya. The cells were grown in high glucose Dulbecco’s Modified Eagle Medium
with 10% fetal bovine serum, 0.5% penicillin/streptomycin and 0.01mg/ml human
recombinant insulin (Life Technologies). Cells were cultured at 37oC and 5% CO2.
MDA-MB-435 is a human melanoma cell line, originally characterized as a breast cancer
cell line [14]. It expresses NIS and exhibits iodide uptake [Goldhawk, unpublished work]
which are characteristics similar to MCF-7 cells [13]. These cells were maintained in low
glucose Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum and 0.5%
penicillin/streptomycin. As indicated above, cells were cultured at 37oC and 5% CO2.
Tumour growth from both cell types has been studied in mouse xenografts using noninvasive in vivo imaging techniques [15, 16] . Thus, the expression system developed in
this thesis may be useful in the future for tracking reporter gene expression during tumour
growth and metastasis.
Transient Transfection
Mammalian cells were transiently transfected using LipofectamineTM 2000 (Invitrogen)
according to the manufacturer’s protocol. Briefly, cells at 70% confluency in 6-well
plates were washed twice with phosphate buffered saline pH 7.4 (PBS) and placed in
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serum-free media. Purified plasmid (0.8µg of either pSF-CMV, pSF or pSF-NISmin, and
20 ng of pRL-SV40) was combined with 3.2 µg LipofectamineTM and added to each well.
Bioluminescence Assay
The Dual-Luciferase® Reporter Assay System kit (Promega) was used to collect cell
lysates and measure luciferase activity following company protocol. Briefly, transfected
cells in 6-well plates were washed with PBS and collected in 500 µl Passive Lysis Buffer
(PLB) supplied with the kit. Lysates were cleared of residual cell debris by centrifugation
at 7000×g at 4 oC for 1 min. The supernatant was transferred to a clean microfuge tube
and stored at -80oC until ready for the assay.
Bioluminescence was measured using the automated Synergy H4 Hybrid Multi-Mode
Microplate Reader (Biotek) and Gen5.11 software (Biotek). Each cell lysate was
measured in triplicate using 20 µl of the sample in each well of a white, opaque 96-well
plate (Greiner Bio-One). The automated plate reader initially injects 100 µl of the
Luciferase assay reagent II (LARII) followed by 100 µl of the Stop & Glo® reagent.
Adding LARII activates firefly luciferase whereas Stop & Glo® reagent quenches firefly
luciferase and activates renilla luciferase. After each addition there is a delay of 5 s and a
slow shake for 10 s prior to the luciferase reading. Lysis buffer (PLB) was used as a
background control and the average measurement was subtracted from cell lysate values.
Firefly luciferase activity values were normalized to renilla luciferase values and
reported as RLU.
Detection of Nkx2.5 by Reverse Transcription-PCR
To verify Nkx2.5 over-expression, MCF-7 cells in 100 mm culture plates were
transfected with 2 µg pCS2-Flag/Nkx2.5 and 8 µg Lipofectamine™. Total RNA was
collected from approximately 1x106 MCF-7 cells, either untransfected or transfected with
pCS2-Flag/Nkx2.5, using the GenElute™ Mammalian Total RNA Miniprep Kit (SigmaAldrich). To avoid contamination with gDNA, samples were digested with DNase I
(Ambion) on the column prior to elution. Total eluted RNA was quantified using the
NanoDrop Spectrophotometer ND-1000 and absorbance at 260 nm, and then stored at 80oC until needed. mRNA was reverse transcribed to give complimentary DNA (cDNA)
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using SuperScript™ II Reverse Transcriptase (Invitrogen) and an Oligo(dT)12-18 Primer
(Invitrogen). The reverse transcription reaction was performed according to the
manufacturer’s protocol, using 1 µg of total RNA. PCR was performed using a forward
Flag-Nkx2.5 primer and the reverse primer Nkx2.5r (Table 2.2.1), 4 µl cDNA, 1 µl
MgCl2, and 3 µl DMSO, for 30 cycles with an annealing temperature of 55oC. Results
were analyzed using agarose gel electrophoresis. β-actin was used as a loading control.
Statistical Analysis
All statistical analyses were conducted using SPSS statistics 22 (IBM). Two-way
ANOVA was used to evaluate the RLU obtained from each treatment (untreated, +RA
and +Nkx2.5) and each transfection (pSF and pSF-NISmin), followed by post hoc tests
using Tukey.

2.3 Results
DNA amplification of human NISmin
hNISmin was amplified from gDNA of MDA-MB-435 cells. The nested PCR results in a
553 bp band of hNISmin as verified by agarose gel electrophoresis (Figure 2.3.1).
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Figure 2.3.1. Amplified human NISmin. A 20 µl sample from the nested PCR was run
on a 1% agarose gel with 1% ethidium bromide. Lane 1 is the 1 Kb-plus DNA ladder
(Life Technologies), lane 2 is empty, and lane 3 has the nested PCR sample. The band at
~550 bp indicates amplified hNISmin. The sizes of select bands in the DNA ladder are
indicated to the left.
Sequence alignment of human and rat NISmin
rNISmin and hNISmin were aligned using Clustal Omega 1.2.1 Multiple Sequence
Alignment tool (Figure 2.3.2) [11, 12]. For rat, the 470 bps immediately upstream of the
NIS gene start codon were defined as the minimal promoter required for Nkx2.5
stimulation of NIS expression [8]. In this study, the hNISmin is from -498 to + 22
relative to the start codon. Aligned sequences were obtained from GenBank (accession
codes AF035228.1 and AF059566.1 for rat and human, respectively) and show 45.47%
identity following alignment. The Nkx2.5 binding sites found in the rat NIS promoter
described by Dentice et al. as N2 and W are boxed [8]. From the rat NIS promoter
sequence (accession code AF035228.1) N2 was identified at -540 to -516 and W at -250
to -226. Of the 23 bases of the W region (-250 to -226), only 8 show identity to hNIS
sequence following alignment. Based on the known DNA binding recognition sequences
of Nkx2.5 [17], a potential binding site of Nkx2.5 on hNISmin was found at -53 to -46
relative to the start codon.
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Figure 2.3.2. Sequence alignment of the NIS minimal promoter (NISmin) from rat
and human. The rat and human NISmin promoter sequences from -470 to the start
codon (+1) and -498 to +22, respectively, were aligned using Clustal Omega software.
Aligned sequences were obtained from GenBank with accession codes AF035228.1 and
AF059566.1 for rat and human, respectively. Asterisks (*) indicate conserved bases
between the 2 species and dashes (-) are gaps introduced as a result of the alignment. The
pairwise score indicating sequence identity is 45.47%. The start codon is shaded in both
human and rat NISmin. The N2 (-540 to -516) and W (-250 to -226) sites on rNISmin,
and the potential Nkx2.5 binding site on hNISmin (-53 to -46) are boxed. The arrow
indicates a C to T base change in the cloned hNISmin that was used in this study.
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Induction of NISmin in RA-treated and Nkx2.5 co-transfected cells
In untreated samples, transfection of cells with pSF-NISmin did not change RLU when
compared to the pSF vector control (Figure 2.3.3b, d). Bioluminescence in these
untreated samples is very small compared to those transfected with the parent vector pSFCMV (Figure 2.3.3 a, c). As expected, a one-way ANOVA of untreated and RA-treated
cells, transfected with pSF-CMV indicates no significant influence of RA on constitutive
luciferase expression in either MCF-7 (F(1,6)=.008, ns) (Figure 2.3.3a.) or MDA-MB435 (F(1,6)=.001, ns) (Figure 2.3.3c.).
hNISmin is also not specifically stimulated by RA-treatment or Nkx2.5 overexpression.
In both MCF-7 (Figure 2.3.3b) and MDA-MB-435 (Figure 2.3.3d) cells, the measured
RLU are very small compared to constitutively expressed luciferase (Figure 2.3.3a and c)
and the vector control outperforms the hNISmin-driven expression. Scrutiny of this
“background” signal using a two-way ANOVA of treatment condition (untreated, +RA,
+Nkx2.5) and transfection (pSF-NISmin and pSF) showed a significant effect of
treatment (F(2,18)=13.11, p < .05) and transfection (F(1,18)=7.7, p < .05) on RLU with
no interaction detected between the two variables (F(2,18)=1.59, ns). However, a post
hoc analysis using Tukey confirms that the vector control responded to treatment
condition even more than the hNISmin-driven vector, arguing against direct stimulation
of this minimal hNIS promoter. For instance, in the MCF-7 vector control, RLU of
Nkx2.5-overexpressing cells were significantly greater than untreated and RA-treated
samples (p < .05, Figure 2.3.3, b) but not so relative to RA-treated samples in hNISmindriven expression. Similar results were found in MDA-MB-435 wherein there was a
significant effect of treatment (F(2,18)=18.16, p < .05) and transfection (F(1,18)=7.11, p
< .05), and no interaction between the two variables (F(2,18)=2.39, ns). In addition,
Tukey’s post hoc analysis indicates that the vector control exhibits significantly greater
RLU in cells overexpressing Nkx2.5 (p < .05) compared to untreated and RA-treated
cells (Figure 2.3.4, d), again suggesting no direct stimulation of hNISmin. (Refer to
Appendix A for raw data.)
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Figure 2.3.3. Induction of NISmin with RA and Nkx2.5. Constitutive firefly luciferase
expression was measured in (a) MCF-7 and (c) and MDA-MB-435 cells transfected with
pSF-CMV (p) alone (untreated) or after treatment with 1 µM tRA (+RA) for 12 h.
Bioluminescence is reported in relative light units (RLU), normalizing firefly luciferase
activity to that of Renilla luciferase. MCF-7 (b) and MDA-MB-435 (d) cells were also
transfected with pSF-NISmin (¢) or the promoterless control pSF (n). These transfected
cells were either incubated with 1 µM tRA (+RA) for 12 h, co-transfected with pCS2Flag/Nkx2.5 to overexpress Nkx2.5 (+Nkx2.5), or left untreated. For all samples, data
points represent the average + SEM. An * indicates significant differences (p < .05)
between samples; n=4.
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RT-PCR of Nkx2.5
An RT-PCR of MCF-7 cells transfected with pCS2-Flag/Nkx2.5 was done to detect
overexpression of Nkx2.5. The primers used (Table 2.2.1, Flag-Nkx2.5 and Nkx2.5r)
span the Flag tag and Nkx2.5 to identify Nkx2.5 expression from the plasmid and exclude
detection of endogenous Nkx2.5. Gel electrophoresis shows a band of the expected size
of the flag tagged Nkx2.5 (930 bp) in an RT-PCR sample of transfected MCF-7 cells and
none in untransfected cells (lanes 2 and 4 respectively, figure 2.3.4). Lack of bands in
samples not treated with reverse transcriptase (RT) identifies no gDNA contamination
ensuring only cDNA was amplified (lanes 3, 5 and 7; figure 2.3.4). Lanes 6 and 7 use
primers for β-actin as an RT-PCR control.

Figure 2.3.4. Overexpression of Nkx2.5. An RT-PCR of MCF-7 cells transfected with
pCS2-Flag/Nkx2.5 demonstrates the overexpression of Nkx2.5. Exclusion of RT revealed
no gDNA contamination. Lane 1 is the 1 Kb-plus DNA ladder (Life Technologies).
Lanes 2 and 3 used RNA extracted from transfected MCF-7 cells. Lanes 4 and 5 used
RNA extracted from untransfected MCF-7 cells. β-actin (lanes 6 and 7) was amplified
from transfected MCF-7 cells and used as a loading control. Flag-Nkx2.5 and Nkx2.5r
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primers were used for samples in lane 2-5. The fragments at ~900 bp and ~150 indicate
amplified Flag-Nkx2.5 and β-actin, respectively.

2.4 Discussion
Dentice et al. showed that a minimal promoter of rat NIS (rNISmin, figure 2.3.2) is able
to activate reporter gene expression by induction of RA and Nkx2.5 in MCF-7 cells [8].
The aforementioned study suggests that these proximal 470 bp immediately upstream of
the start codon, are activated by the binding of Nkx2.5 in 2 regions of the sequence, N2
and W, notwithstanding the upstream location of N2. Nevertheless, they demonstrated
that tRA increases Nkx2.5 expression in MCF-7 cells, which in turn activated rNISmin.
This has yet to be demonstrated with hNISmin (hNISmin, Figures 2.3.1 and 2.3.2).
Understanding how human NIS is induced in breast cancer will help in developing
imaging and therapeutic tools for managing the disease. This thesis chapter examines the
effect of RA and the overexpression of Nkx2.5 on hNISmin in two cancer cell lines:
MCF-7 and MDA-MB-435. Activation of hNISmin was monitored by firefly luciferase
reporter gene expression to provide a quantitative measure of any changes in promoter
stimulation.
Sequence alignment of human and rat NISmin.
The proximal sequence of the rat and human NIS promoter have an identity score of
approximately 46% indicating substantial variation in the two sequences. Nevertheless,
Dentice et al. showed that Nkx2.5 binds to 2 regions on the rat NIS promoter sequence by
EMSA. These regions, named N2 and W, were matched by the authors to nucleotides 446 to -423 and -250 to -230, respectively, relative to the start codon (+1) and contain the
following nucleotide sequences: CAAGAGAACCTGAGTGCCTCCCAC (N2) and
AGACACGAGTGTTCCCCCACCCCG (W) (Figure 2.3.2) [8]. However, further
sequence analysis of the rat NIS promoter identifies the N2 sequence at -540 to -516,
unlike the region identified by Dentice et al. Despite this discrepancy, neither of these
sequences, N2 or W, are present in the hNISmin (Figure 2.3.2) The literature indicates
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that Nkx2.5 binds to the sequence TNAAGTG and C(A/T)TTAATTN [17]. A closer look
at the minimal human NIS promoter identifies a potential Nkx2.5 binding site at -53 with
the sequence TCAAGCG, though this has not been validated experimentally by a binding
assay like EMSA or chromatin immunoprecipitation (ChIP).
Induction of hNISmin in MCF-7 and MDA-MB-435
In both MCF-7 and MDA-MB-435 cells, pSF-NISmin activity is less than the
background signal from the promoterless vector control (pSF), indicating virtually no
endogenous activation of the hNISmin. Treatment with 1µM RA for 12 h had no
stimulatory effect on NISmin-driven luciferase expression. Overexpression of Nkx2.5
had the same negligible effect as RA treatment (Figure 2.3.3. b, d). Interestingly, the
promoterless vector control gave significantly greater bioluminescence than NISmindriven expression; although, no biologically-relevant response to RA treatment or Nkx2.5
overexpression can be attributed to this negative control and is considered background
signal. We conclude that hNISmin was not specifically induced by RA treatment or
Nkx2.5 overexpression in these cancer cell lines.
In similar work by Dentice et al. using the rat NIS promoter and luciferase reporter
constructs in MCF-7 cells, deletion analysis of this promoter in combination with Nkx2.5
overexpression showed that maximal activation occurred using the proximal 470 bp, 5' to
the start of NIS gene expression (rNISmin) [8]. This minimal promoter was activated
approximately 40-fold over that of the constitutively expressed control. Furthermore, RA
treatment of MCF-7 cells transfected with this minimal reporter construct resulted in a
60-fold activation of luciferase reporter gene expression. The primary difference between
their methods and the one discussed in this chapter lies with the species specificity of the
minimal promoter. A study by Alotaibi et al. looked at the untranslated regions of the
human NIS gene [9]. They found a functional RARE in the first intron of the gene (+927
to +1222). Use of this region in a luciferase reporter in MCF-7 cells treated with 1µM RA
for 24 hours resulted in a 20-fold activation in bioluminescence. In addition, in this study
RA also induced a 1.1 kb sequence within the human NIS promoter (-1138 to -42).
Deletion mutations of this 1.1 kb region suggested that the entire sequence is necessary
for the RA response, indicating a synergistic interaction with other sequences within the
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1.1 kb region. This report suggests that RA stimulates a larger region of the human NIS
promoter than used in the present study and that RA induction may be independent of
Nkx2.5 activity.
The lack of response of hNISmin (-498 to +22) to RA or Nkx2.5 may be explained by
differential regulation of NIS between species. The overall sequence similarity between
the full rat and human NIS promoters is only 11.8%; although, both human and rat NIS
expression in thyroid tissue are induced by TSH [7]. In addition, the thyroid transcription
factor-1 (TTF-1) directly activates the rat NIS promoter [18]. TTF-1 also induces the
expression of thyroglobulin (Tg) and thyroperoxidase (TPO), proteins necessary for
iodide accumulation in the thyroid gland. TTF-1, however, does not activate the human
NIS promoter [19]. Thus, induction of the NIS promoter appears to differ between rats
and humans. A more extensive investigation of the full human NIS promoter would be
required to determine if it indeed responds to Nkx2.5.
Induction of NIS expression may be important in the development of therapy and
imaging tools for managing breast cancer as well as for understanding transcription
factors involved in pathology. In thyroid cancer, TSH stimulates functional NIS
expression making the disease relatively manageable with a mortality rate of 3% when
treated [2]. NIS in breast cancer is not inducible in the same manner [7, 20]. In addition,
differences in NIS promoter regulation between species need to be scrutinized.

2.5 Conclusion
hNISmin (-498 to +22) does not respond to RA or Nkx2.5 overexpression in the breast
cancer cell line MCF-7 and the melanoma cell line MDA-MB-435, and thus does not
support our hypothesis. Using a luciferase reporter gene construct driven by hNISmin,
RLU did not differ from the promoterless, negative control vector. This differs from the
results found with rNISmin [8]. The sequence identity of NISmin between the two
species is 45.47%, from –470 to +1 of rNISmin and -498 to +22 of hNISmin, and the
hNISmin sequence does not faithfully conserve the binding regions of Nkx2.5 identified
in rNISmin.
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Chapter 3

3

Creation of an HA-MagA-myc vector2

3.1 Introduction
The development of MRI reporter gene expression will permit non-invasive, temporal
and spatial detection of specific cellular (transcription factor) activity. This will provide a
powerful tool for studying disease progression and monitoring therapy [1–3]. The
magnetotactic bacterial gene MagA has demonstrated potential as an MRI reporter gene
[4–8]. MagA was originally believed to be involved in magnetosome iron transport [9,
10]. Overexpression of MagA in mammalian cell lines is non-cytotoxic and provides MR
detectable contrast [4–8]. Its expression in multiple mammalian cell lines results in
cellular iron increases in response to an iron supplement [4, 7, 8]. Iron quantification by
inductively-coupled plasma mass spectrometry (ICP-MS) revealed that when the human
melanoma cell line MDA-MB-435 was cultured in iron-supplemented medium, cells
retained approximately 14-fold more iron than cells without iron supplementation [7].
Furthermore, these iron-supplemented, MagA-expressing cells displayed magnetic
sensitivity causing a change in transverse relaxation rates in MRI. Repetitive imaging of
tumour xenografts in mice showed that MagA-expressing tumours had increased MR
contrast, measured by fractional void volume, a week prior to that of control tumours [6].
While previous work has employed constitutive expression of the MagA gene [5–7],
creating MagA reporter gene expression using a more selective promoter will enable noninvasive detection of transcription factor activity involved in disease processes such as
tumour development and progression.

2

Chapter 3 is unpublished work
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Expression of MagA, tagged with epitopes that permit protein detection with
commercial antibodies, will verify reporter gene expression independently of MRI. In
much of the previous work with MagA as a reporter gene for MRI, protein analysis was
hampered by the lack of a MagA antibody. Synthesis of a doubly-tagged MagA using
well-characterized epitopes enables the verification of full-length protein expression in
addition to other structure function analyses. HA and myc are two such epitopes. The HA
and myc tags are made-up of 9 and 10 amino-acids, respectively [11, 12]. Commercial
antibodies are available for these tags and have been successfully used in protein
analyses, such as Western blot, immunocytochemistry and immunoprecipitation [13].
These techniques may be used to detect, isolate and quantify protein. This will enable
characterization of MagA over-expression in mammalian cells in vitro and in vivo.
Furthermore, with tagged MagA reporter gene expression, to detect transcription factors
involved in disease, the histopathology of animal models may be compared to changes in
MRI contrast.
This chapter describes the cloning of an HA- and myc-tagged MagA expression
construct. The functionality of doubly tagged MagA is also examined in MCF-7 cells,
cultured in the presence and absence of iron supplementation followed by elemental iron
analysis. We hypothesized that the addition of epitope tags onto MagA will not alter its
function. Iron uptake in cells transfected with doubly tagged MagA should not differ
from cells transfected with untagged MagA.

3.2 Methods
Construction of an HA-MagA-myc expression vector
The cloning strategy is presented in Figure 3.2.1. In the first step, MagA from the
previously described pEGFP-C3/MagA expression vector [5] was inserted into the MCS
of a modified pGAD-T7, in which the EcoR1 site was placed in the second position to
preserve the reading frame of MagA. Thus, vector and insert fragments were prepared
using restriction enzyme digestion with EcoRI and the hybrid construct contained MagA
in-frame and downstream of the HA sequence in pGAD-T7. HA-MagA was then
directionally subcloned from pGAD-T7 into pEGFP-C2, downstream of EGFP, using a
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digest with BglII and BamHI. This intermediate EGFP-HA-MagA expression vector will
be useful in future work for direct optical imaging of MagA expression. Following this
step, HA-MagA was subcloned from pEGFP-C2 using BglII and BamHI and religated in
pCDNA3.1/myc-His A+ at the BamHI site. This inserted HA-MagA upstream but out-offrame with myc-His epitopes in the target vector. In addition, the MagA insert retained a
3' stop codon from the initial pEGFP-C3 vector. To correct the 3' reading frame and
prevent truncation of the myc and His tags, site-directed mutagenesis was used to remove
the stop codon and insert an XbaI restriction enzyme site. The Quick Change II SiteDirected Mutagenesis Kit by Agilent was used as per the manufacturer’s instructions.
Custom primers were synthesized by Sigma-Aldrich and resuspended in sterile water to a
concentration of 10 μM. The sequences for the forward and reverse primers, respectively,
reading from 5’ to 3’ are the following:
CCTGGCTCTGGAATTTCAACTTCTAGACATCGTCAAGGGCG and
CGCCCTTGACGATGTCTAGAAGTTGAAATTCCAGAGCCAGG. The inserted XbaI
site allowed for a fragment of the vector between HA-MagA and myc-His to be excised
by an XbaI digest, thereby bringing HA-MagA in-frame with myc-His (Figure 3.2.1). In
addition, the primers used for mutagenesis were designed to restore the last 2 codons of
MagA, serine and threonine, that were removed during the original cloning of MagA
from AMB-1 [5].
Restriction enzymes were purchased from Invitrogen and used as per the manufacturer’s
instructions. Plasmid vectors and manipulations of nucleotide sequence were validated by
as described in section 2.2, DNA Sequencing.
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Figure 3.2.1: Schematic showing the cloning strategy for the construction of HAMagA-myc. Briefly, MagA from pEGFP-C3 as previously described [5] was cloned into
pGAD-T7 to form HA-MagA. As an intermediate step, it was then inserted into pEGFPC2. From pEGFP-C2, HA-MagA was cloned into pcDNA3.1/myc-HisA+. The myc-His
tag was made in-frame with respect to HA-MagA using site-directed mutagenesis and
XbaI restriction digestion.
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Cell culture and transient transfection
The breast cancer cell line MCF-7 was cultured in the same manner as described in
section 2.2, Cell Culture. Mammalian cells were transiently transfected using
LipofectamineTM 2000 (Invitrogen) according to the manufacturer’s protocol. Briefly,
cells were grown to 60% confluency in 100 mm plates, washed twice with PBS and
placed in serum-free medium. Either 4 µg of pcDNA3.1mycHisA+/HA-MagA or
pcDNA3.1Zeo+/MagA was used for transfection with 16 µg LipofectamineTM. Much of
the prior work characterizing MagA as an MRI contrast agent has been done with the
latter plasmid [6, 7], expressing an untagged MagA. Cells were transfected with
pcDNA3.1Zeo+/MagA to compare the functionality of untagged and doubly-tagged
MagA in terms of the ability to retain iron. The transfection solution was added to each
plate and incubated at 37oC with 5% CO2 for 12 h, after which time the solution was
replaced with serum-rich medium. Cells were cultured either with (+ Fe) or without (- Fe)
iron supplementation. To satisfy the former condition, medium containing 250 µM ferric
nitrate was introduced 24 h post-transfection for a further 48 h. All plates were harvested
on day 3 post-transfection.
Analysis of iron content
MCF-7 cells, both transfected and untransfected, were cultured as described above and
collected from confluent 100 mm plates using a rubber policeman and 850 µl
radioimmunoprecipitation assay (RIPA) buffer containing 150 µl Complete Mini protease
inhibitor cocktail (Roche Diagnostic Systems), solubilized according to the company’s
instructions. Samples were sonicated for 12 s using a Sonic Dismembrator model 500
(Fisher Scientific) at an amplitude of 29%.
Iron content of cell lysates was quantified by inductively-coupled plasma mass
spectrometry (ICP-MS) by the Analytical Services Laboratory of Western University
(London, Ontario). Protein was quantified using the BCA assay [14] and used to
normalize iron quantity. Zinc was also quantified as a comparison to iron. The results
were evaluated with a two-way ANOVA using SPSS version 22.0. Significance was
noted at p < .05. Post-hoc analysis was done using Tukey.
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3.3 Results
The amino acid sequence of HA-MagA-myc
Plasmids, including intermediate constructs, were sequenced throughout the process of
creating the doubly tagged MagA. Figure 3.3.1 shows the final amino acid sequence of
pcDNA3.1myc-His A+/HA-MagA, based on the nucleotide sequence, from the start
residue (M) preceding the HA-tag through to the His tag. The nucleotide sequence was
converted to an amino acid sequence using the National Centre for Biotechnology
Information Open Reading Frame (NCBI ORF)-finder
(www.ncbi.nlm.nih.gov/projects/gorf/). The sequence shows that HA, MagA and myc are
all in the same reading frame. Sequence alignment of the cloned HA-MagA-myc with the
amino acid sequence of MagA cDNA obtained from GenBank (accession code
AB001694.1) was done using Clustal Omega 1.2.1 Multiple Sequence Alignment tool
[15, 16]. The two MagA sequences, excluding the tags, have an identity score of 97.25%.
The residues corresponding to a unique PstI site (LQ) in the nucleotide sequence, that is
in-frame, are boxed. The residues corresponding to the XbaI site in the nucleotide
sequence, boxed SR, is where the vector was religated following mutagenesis and
restriction digestion to bring myc-His in-frame with HA-MagA. While restriction
enzymes do not recognize amino acids, these particular restriction sites have been pointed
out here in order to note their appropriate location in the nucleotide sequence (Appendix
B). The arrow identifies a conserved glutamic acid (E) at residue 137 which was
previously identified as important for preserving MR contrast activity [5].
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Figure 3.3.1. Amino acid sequence of cloned HA-MagA-myc and alignment with
MagA. The amino acid sequence of MagA was translated from the GenBank cDNA entry
(accession code AB001694.1) (MagA). The amino acid sequence of cloned HA-MagAmyc was translated from nucleotide sequencing reports from the London Regional
Genomics Centre (Western University), piecing together regions of overlapping sequence
to obtain the fully sequenced construct. Numbers on the right-hand side indicate residue
number of MagA and cloned HA-MagA-myc relative to the respective start methionine
(M). The N-terminal HA and C-terminal myc and His tags are shaded. Residues
corresponding to nucleotide sequence restriction sites for PstI (LQ) and XbaI (SR) are
boxed. The arrow identifies a glutamic acid at residue 137, as appropriate. Asterisks (*)
indicate identical residues; colons (:) identify residues with conservative substitutions;
and spaces identify residues with dissimilar properties. Dashes (-) indicate no alignment.
The two sequences, excluding the HA, myc and His tags, have a pairwise identity score
of 97.25%.
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Elemental iron and zinc analysis
Iron supplemented samples transfected with HA-MagA-myc or MagA have greater iron
content than untransfected samples (Table 3.3.1). A two-way ANOVA of iron content
indicates significant main effects for treatment (+/- Fe) (F(1,12) = 51.82, p < .05, η2 = .54
, power = 1.00 ) and transfection (MCF-7, HA-MagA-myc, MagA) (F(2,12) = 8.25, p <
.05, η2 = .17 , power = .90). There was also a significant interaction between treatment
and transfection (F(2,12) = 8.22, p < .05, η2 = .17 , power = .90). A post hoc analysis
using Tukey indicated no significant difference in iron content between HA-MagA-myc
and MagA samples but confirmed a significantly lower iron content in untransfected
MCF-7 (p < .05). A test for simple main effects indicates a significant difference between
HA-MagA-myc + Fe and MagA + Fe compared to unsupplemented (-Fe) samples and the
parental controls (p < .05). As anticipated, there was no significant difference in iron
content between HA-MagA-myc + Fe and MagA + Fe samples.
With regards to zinc content (Table 3.3.2), there are no significant main effects for
treatment (F(1,12) = .63, ns, η2 = 0.2, power = .11) or transfection (F(2,12) = 2.38, ns, η2
= .17 , power = .39). However, there is a significant interaction between treatment and
transfection (F(2,12) = 4.74, p < .05, η2 = .35 , power = .68). A test for simple main
effects indicates a significant difference between zinc content in + Fe and - Fe MagAexpressing samples (p < .05), while no significant differences were found for the other
samples.
Table 3.3.1. Iron analysis* of untransfected and transfected cells with or without
iron supplementation¢.
	
  

MCF-‐7	
  

HA-‐MagA-‐myc^	
  

MagA^	
  

-‐	
  Fe	
  

0.095	
  ±	
  .023	
  

0.114	
  ±	
  .020	
  

0.088	
  ±	
  .008	
  

+	
  Fe	
  

0.312	
  ±	
  .023	
  

1.328	
  ±	
  .285	
  

1.586	
  ±	
  .287	
  

*Element analyzed by ICP-MS; protein quantified by BCA assay.
Values are reported as µg iron/mg protein; mean ± SEM
¢

n=3 for all samples

^Significant difference (p < .05) between – Fe and + Fe samples
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Table 3.3.2. Zinc analysis* of untransfected and transfected cells with or without
iron supplementation¢.
	
  

MCF-‐7	
  

HA-‐MagA-‐myc	
  

MagA^	
  

-‐	
  Fe	
  

0.343	
  ±	
  .034	
  

0.466	
  ±	
  .047	
  

0.620	
  ±	
  .032	
  

+	
  Fe	
  

0.393	
  ±	
  .033	
  

0.574	
  ±	
  .139	
  

0.323	
  ±	
  .076	
  

* Element analyzed by ICP-MS; protein quantified by BCA assay.
Values are reported as µg zinc/mg protein; mean ± SEM
¢

n=3 for all samples

^Significant difference (p < .05) between – Fe and + Fe samples.

3.4 Discussion
This chapter describes the synthesis of a doubly tagged MagA and its function in
transiently transfected, iron-supplemented cells. MagA is a putative iron transport
protein. Much of the work in the development of MagA as an MRI reporter gene was
achieved by expressing an untagged protein [6, 7]. The lack of a commercial antibody for
MagA has limited the protein analysis that may be done to more fully understand the
function of MagA when overexpressed in mammalian cells. Tagging MagA will enable
detection of protein expression. With the HA- and myc- epitopes, changes in MRI may be
directly attributed to MagA protein expression using commercial anti-HA and anti-myc
antibodies. In addition, with the use of methods such as Western blot,
immunocytochemistry and co-immunoprecipitation, the tagged-protein may be identified
in cell lysates or tissue homogenates, localized in situ, and partially characterized with
respect to protein-protein interactions. An epitope on both C- and N-termini will also help
identify any post-translational modifications of MagA that involve proteolytic cleavage.
These are important in characterizing MagA overexpression in mammalian cells and
finding ways to optimize its function as an MR reporter gene. Furthermore, the HAMagA-myc vector may also be useful for investigating MagA expression and function in
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magnetotactic bacteria. Iron accumulation in HA-MagA-myc-transfected MCF-7 cells
demonstrates the functionality of the doubly tagged protein.
Amino-acid sequence of HA-MagA-myc
Sequencing results verified that HA and myc epitopes flank, and are in-frame with,
MagA cDNA. Expression of the gene will result in MagA with an HA epitope on the Nterminus and a myc epitope on the C-terminus. Epitopes on both ends of the protein will
enable detection of the full protein and may be used in analyzing post-translational
modifications. Alignment of the corresponding amino acid sequence of cloned HAMagA-myc with the magnetotactic bacterial sequence of MagA deposited in GenBank
identifies 12 differences out of 436 amino-acids. Of these, 8 are residues that differ
conservatively, retaining similar properties with respect to polarity of the R-group [17].
In addition, among the sequences of MagA clones deposited in GenBank (accession
codes AB001694.1, AB001695.1, AB001696.1), there are some differences in amino acid
residues so that identity scores range from 87.08% to 94.26%. The glutamic acid (E)
residue at 137 and the unique PstI site (LQ) identified in figure 3.3.1 are, however,
conserved. Mutation of the conserved glutamic acid (E), indicated by the arrow at residue
137 of MagA, and 168 of HA-MagA-myc, to a valine results in decreased signal voids as
demonstrated in N2A cells using 11T micro-MRI [5]. Although the sequence identity
reported here for a modified MagA expression construct is great (over 97%), Mason et al.
reported that a polyhistidine tag on the C-terminus of human transferrin affected the rate
at which the protein released iron; whereas, a tag on the N-terminus did not. In addition,
tags on either N- or C-termini did not influence the ability of modified transferrin to bind
transferrin receptor [18]. In another study, location and length of a polyhistidine tag did
not affect the expression and localization of an E. coli water channel membrane protein
aquaporin Z, but length did affect its oligomerization and may be due to a change in ionic
behaviour [19]. How epitope tags affect a protein depends on the protein and the tag. It is
important to verify functionality of the protein of interest following the addition of tags.
As discussed below, the iron uptake ability of doubly-tagged MagA has been examined.
HA- and myc tags are widely used epitopes for studies requiring protein analyses [11–
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13]. The HA- and myc- tags on MagA will permit characterization of its expression in
mammalian cells.
Iron Analysis
The ability of HA-MagA-myc-expressing MCF-7 cells to accumulate iron upon culture in
the presence of an extracellular iron supplement was determined by ICP-MS and
compared to that of cells expressing an untagged MagA and to the untransfected parental
control (Table 3.3.1). Among iron-supplemented samples, there is a 4 to 5-fold increase
in iron content in HA-MagA-myc- and MagA-expressing cells compared to untransfected
cells. This result provides the first characterization of transiently-expressed MagA
activity in MCF-7 cells and shows that MagA, tagged or untagged, is able to retain iron
following short-term supplementation; however, the sample size is small. These data are
consistent with MagA function in every other mammalian cell type examined to date and
were submitted to the United States Patent and Trademark Office as evidence in support
of patent filing # 12/303793 [20]. As expected, there was no significant difference in iron
content between iron-supplemented HA-MagA-myc and untagged MagA.
There was a significant difference in zinc content in iron-supplemented and nonsupplemented MagA-expressing cells (Table 3.3.2). Since zinc content changes with
mitosis and apoptosis [21], a significant difference in cellular zinc may reflect differences
in overall growth between iron-supplemented and unsupplemented MagA-expressing
samples. In addition, cellular uptake of zinc is related to the uptake of non-transferrin
bound iron [22]. High cellular iron accumulation in MagA-expressing cells may therefore
be affecting zinc transport. Consistent with this, Sengupta et al. showed that transferrin
receptor is appropriately down-regulated in MDA-MB-435 cells cultured in the presence
of iron supplementation [7].
Iron accumulation by HA-MagA-myc will determine the effect of the protein activity as
an MRI contrast agent. Sengupta et al. transfected the mammalian cell line MDA-MB435 with the previously described untagged MagA [7]. Iron supplementation (250 µM
ferric nitrate/medium) of stably-transfected cells for 5 days showed a significant increase
in iron content compared to unsupplemented cells (0.667 and 0.047 µg Fe/mg protein,
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respectively), a 14-fold increase whereas the results in this thesis found a 12- and 18-fold
increase for HA-MagA-myc and MagA transiently transfected cells, respectively.

3.5 Conclusion
Sequencing and iron analysis demonstrated the successful synthesis of a functional HAMagA-myc. Significant iron accumulation in cells transfected with HA-MagA-myc
demonstrates the functionality of the construct. The epitope tags on MagA do not affect
its ability to accumulate iron.
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Chapter 4

4

Summary and Future Work

4.1 Summary of Findings
The objective of this project was to synthesize the DNA constructs necessary for the
development of MRI reporter gene expression. The promoter studied in this thesis was
the minimal promoter of human NIS and, in particular, its response to the transcription
factor Nkx2.5 and RA hormonal stimulation in a breast cancer cell line, MCF-7. The
MRI reporter gene used was MagA and in this thesis it was fused with HA- and mycepitope tags to facilitate future detection of MagA protein expression using commercial
antibodies.
Nkx2.5 is a transcription factor normally expressed in developing cardiomyocytes [1];
although, a potential role in cancer has been reported but not well defined. In the breast
cancer cell line, MCF-7, Nkx2.5 expression was apparently induced by RA and reported
using the rNISmin to drive luciferase reporter gene expression [2]. Such activation has
yet to be demonstrated with hNISmin, which shares only partial sequence similarity with
rNISmin over these regions (identity is about 46%) but does have another putative
Nkx2.5 recognition site within this minimal promoter sequence identified based on the
known Nkx2.5 binding site (Figure 2.3.2). While not much is known about the role of
Nkx2.5 in breast cancer, induction of NIS in the disease could be important for the
development of radioiodide therapy for detecting and treating the disease. NIS is
expressed in 80% of breast cancers and breast cancer brain metastases [3, 4]. In this
thesis, hNISmin was cloned into a luciferase reporter gene expression vector and
transfected into MCF-7, and MDA-MB-435, a human carcinoma cell line. Activation of
hNISmin was compared to constitutive luciferase expression and a promoterlessluciferase vector control. Transfected samples were treated with 1 µM RA for 12 hours or
co-transfected with an Nkx2.5 overexpression vector. Results from the measurement of
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luciferase activity indicate that neither RA nor Nkx2.5 activate human NISmin in MCF-7
or MDA-MB-435 cells.
These results are unlike that found with rNISmin in MCF-7 cells where RA-treatment
alone increased activation ~60-fold and Nkx2.5 overexpression alone increased activation
~40-fold [2]. An alignment of rat and human NISmin revealed the sequences were 46%
homologous. Furthermore, upon scrutiny of hNISmin, it was found that the sequence
lacked the same Nkx2.5 binding regions identified in rNISmin but had a potential Nkx2.5
binding site (TCAAGCG) at -46 to -52 bp relative to the start codon (figure 2.3.2).
However, the results suggest that Nkx2.5 overexpression may not activate hNISmin. An
RT-PCR of MCF-7 cells transfected with pCS2-Flag/Nkx2.5 shows overexpression of
flag-tagged Nkx2.5; however, it is possible that sufficient Nkx2.5 was not overexpressed.
The difference between the published response of rNISmin to RA and Nkx2.5, and the
response of hNISmin to RA and Nkx2.5 investigated in this thesis, is possibly due to
differential regulation of NISmin between species. Aspects of NIS regulation differ
between tissues and between species [5–7].
Epitopes were added onto each end of the MRI reporter gene MagA, and the functionality
of this tagged-MagA was tested. HA- and myc- epitopes were cloned onto the 5’ and 3’
ends of MagA, respectively. MCF-7 cells were transfected with HA-MagA-myc and
cultured for 48 h with or without iron-supplementation (250 µM Fe(NO3)3). Iron content
was measured using ICP-MS and normalized to protein. Zinc was also measured as a
comparison to iron. These results showed that iron-supplemented HA-MagA-mycexpressing cells accumulated more iron than untransfected, and non-iron supplemented
cells. Furthermore, HA-MagA-myc-expressing, iron-supplemented cells accumulated a
similar amount of iron as iron-supplemented cells transfected with untagged MagA;
however, any potential differences in iron uptake are likely too small to detect with our
limited number of samples (n=3). In other words, the HA-MagA-myc construct should be
able to function similarly to MagA in the context of an MRI reporter gene. In MCF-7
cells, there was a significant difference in cellular zinc between iron-supplemented and
unsupplemented cells transfected with untagged MagA. While this has not been
documented in other cell types examined, such as MDA-MB-435 [8] and P19
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(unpublished data), iron accumulation in MCF-7 cells may affect zinc transport [9]. More
work is needed to verify this.

4.2 Significance of Findings
Expression of the epitope-tagged HA-MagA-myc will enable detection of the MRI
reporter MagA using commercial antibodies and immunological techniques such as
Western blot, co-immunoprecipitation and immunocytochemistry. In addition, due to the
expression of an epitope on each terminus of the protein, post-translational
modification(s) such as proteolytic cleavage may be assessed. There is currently very
little information on the fate of MagA in mammalian cells apart from its iron uptake
function. A greater understanding of the rate and manner of MagA protein turnover may
ultimately lead to improvements in MR detection, contrast signal longevity and the
threshold for cellular iron uptake. Moreover, for the detection of transcription factor
activity involved in animal models of disease, a change in MRI signal using MagA
reporter gene expression could be correlated to MagA function and tissue localization by
studying histopathology. In summary, characterization of MagA expression in
mammalian cell lines will help in understanding its function and how it may be optimized
as an MRI reporter gene.
MRI reporter gene expression will enable non-invasive detection of the molecular
activities of cells. Specifically, after it is fully developed, this technology may be used to
monitor transcriptional activation in cells through the expression of protein that produces
a detectable phenotype (Figure 1.1.1). This may be used to study signaling pathways
within cells and animal models, which is particularly relevant to cancer since most
oncogenic signaling pathways converge on sets of transcription factors that ultimately
control tumour formation, progression and metastasis [10]. The use of specific response
elements or promoters in the reporter gene expression construct will track transcription
factor activity that may be involved in the development and progression of disease. Thus,
application of reporter gene expression technology to MRI will provide a tool for
studying molecular activity non-invasively.
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4.3 Future Work
Characterization of hNISmin and the synthesis of an HA-MagA-myc construct contribute
to the development of MRI reporter gene expression to track specific molecular activity
in cells. hNISmin was inserted into a modular SnapFast™ vector with a MCS and IRES
to enable expression of two reporter genes, like MagA and firefly luciferase (Figure
2.2.1, pSF-NISmin). The IRES permits the expression of any 2 genes under the control of
a single promoter [11]. Future work involves subcloning HA-MagA-myc into the MCS of
this vector to create a reporter construct expressing both MagA and luciferase, for multimodality detection using MRI and bioluminescence. Due to the modular nature of this
vector, the CMV promoter may be substituted with other sequence(s) of choice using
standard cloning technique, to track Nkx2.5 or other transcription factor activity.
Luciferase activity may be quantified and used as a comparison to changes in cellular
iron and MR contrast derived from MagA expression. Luciferase activity is proportional
to the concentration of the enzyme [12]; correlating this with changes in transverse
relaxation rates resulting from MagA expression and iron supplementation may provide
insight into how iron accumulation and MagA function affect the MRI signal.
Understanding how MagA expression is regulated in mammalian cell lines will help
improve the use of MagA as an MRI reporter gene.
The SnapFast™ design provides a versatile vector backbone for convenient manipulation
of its functional components: promoter, reporter gene(s) and selection marker(s). In
theory, any number of different promoters or response elements may be cloned into the
vector to study the activity of transcription factors involved in cellular signaling and the
onset of phenotypic changes in health or disease. The design permits the application of
dual reporter gene expression for multi-modality imaging to study proteins and molecular
pathways. For instance, in stem cell therapy there is a need to temporally and spatially
detect live transplanted cells, their engraftment into the injured tissue, and their
differentiation into functional cells of interest. The transcription factor Nkx2.5 is
normally expressed in the developing and adult cardiac muscle, and is involved in the
transcription of β-myosin heavy chain, a cardiac specific gene [13]. Nkx2.5 expression
was observed during the differentiation of mesenchymal stem cells into cardiomyocytes
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[14]. A promoter responding to cardiac Nkx2.5 may be used to detect, using MRI
reporter gene expression, the differentiation of transplanted stem cells for the repair of
myocardial infarction. Similarly, the tool may be used in studying proteins involved in
disease. One example is TWIST, a protein that is believed to be involved in the
metastasis of breast cancer by activating the expression of a marker of the epithelial to
mesenchymal transition [15]. TWIST was found to be overexpressed in circulating
tumour cells from patients with metastatic breast cancer [15]. Studying the temporal and
spatial expression of TWIST in an animal model of breast cancer metastasis using MagA
reporter gene expression will help delineate the process of metastasis and the role that
TWIST plays.
In summary, the development of a modular MRI reporter gene expression construct will
enable the study of any number of transcription factors of interest. Such a tool may be
used to investigate molecular mechanisms involved in health, in the development and
progression of disease, and in the detection of differentiation and migration of
transplanted cells.

4.4 Conclusion
Towards the development of MRI reporter gene expression using MagA to track Nkx2.5
expression in breast cancer, induction of a minimal human NIS promoter sequence by
Nkx2.5 and RA was investigated. In addition, an HA- and myc-epitope-tagged MagA
gene construct was prepared for insertion into a modular reporter vector. Results
presented in this thesis show that the chosen human NIS minimal promoter (-498 to +22)
is not activated by Nkx2.5 or RA, unlike what was reported for a similar region of the rat
NIS minimal promoter (-470 to +1) [2]. Comparative iron analyses of MCF-7 cells
constitutively expressing either HA-MagA-myc or the untagged MagA demonstrated that
these epitope tags do not alter the ability of MagA to accumulate iron in this cell line.
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Appendices
Appendix A: Raw Data from Bioluminescence Experiments
MCF-7 and MDA-MB-435 cells were transfected with either pSF-CMV, pSF-NISmin or
pSF. These plasmids have a gene for firefly luciferase. All samples were co-transfected
with pRL-SV40, a plasmid constitutively expressing Renilla luciferase. Bioluminescence
was measured using the Dual-Luciferase® Reporter Assay System kit by Promega
according to the company’s protocol and Synergy H4 Hybrid Multi-Mode Microplate
Reader (Biotek). The Microplate reader gives arbitrary values referred to in this section
as light units. Normalized luciferase is the firefly luciferase value over the corresponding
Renilla luciferase value. Samples were treated with either tRA, Nkx2.5 over-expression
or left untreated. Each sample was measured in triplicate with a sample size of 4 for each
treatment type for both cell types.
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Table A.1. Bioluminescence of untreated MCF-7 cells.

* Values reported as light units; arbitrary values
^ Values reported as relative light units (RLU)
• AVE: average; STDEV: standard deviation; SEM: standard error of the mean
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Table A.2. Bioluminescence of tRA-treated MCF-7 cells.

* Values reported as light units, arbitrary values
^ Values reported as relative light units (RLU)
• AVE: average; STDEV: standard deviation; SEM: standard error of the mean
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Table A.3. Bioluminescence of MCF-7 cells over-expressing Nkx2.5.

* Values reported as light units, arbitrary values
^ Values reported as relative light units (RLU)
• AVE: average; STDEV: standard deviation; SEM: standard error of the mean
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Table A.4. Bioluminescence of untreated MDA-MB-435 cells.

* Values reported as light units, arbitrary values
^ Values reported as relative light units (RLU)
• AVE: average; STDEV: standard deviation; SEM: standard error of the mean
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Table A.5. Bioluminescence of tRA-treated MDA-MB-435 cells.

* Values reported as light units, arbitrary values
^ Values reported as relative light units (RLU)
• AVE: average; STDEV: standard deviation; SEM: standard error of the mean
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Table A.6. Bioluminescence of MDA-MB-435 cells over-expressing Nkx2.5.

* Values reported as light units, arbitrary values
^ Values reported as relative light units (RLU)
• AVE: average; STDEV: standard deviation; SEM: standard error of the mean
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Appendix B: HA-MagA-myc sequence

Figure B. HA-MagA-myc nucleotide sequence in pcDNA3.1myc-His A+/HA-MagA.
The sequence is from the 5ʹ′ insertion site to the stop codon following the His tag. The
numbers indicate the location of the sequence in the plasmid. The HA, myc and His tags
are in bold, and MagA is underlined. The start and stop codons are shaded. Unique
restriction sites within this region of the plasmid are identified.
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